UK drug exports to US spared tariffs under deal critics say will cost NHS billions
‘Partnership’ on drug pricing also gives patients in Britain greater access to potentially life-extending treatments

TL;DR
- British drug exports to the US will not face tariffs under a new UK-US medicines deal.
- The deal aims to increase patient access to potentially life-extending drugs in the UK.
- The National Institute for Health and Care Excellence (Nice) has increased the NHS spending limit per treatment from £30,000 to £35,000 annually.
- The government anticipates the deal will protect 50,000 pharmaceutical jobs and encourage investment in the UK.
- Critics warn the increased spending commitment on new medicines (£9bn a year by 2035) will be a significant cost to the NHS, outweighing the benefits of avoiding £5bn in tariffs.
- The Liberal Democrats and campaign groups have raised concerns about transparency and the potential financial impact on the NHS.
- The full text of the deal was not immediately made available, leading to criticism about secrecy.
- The first two drugs approved under the new regime are for brain cancer and a rare stomach cancer.